臓がん患者におけるKRAS変異の分子特徴と予後的影響:多群分析からの洞察

関連する実験動画

Updated: Sep 10, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Yubo Jiang¹, Gang Mai², Xiaokai Zhao^3,4

¹Department of Gastroenterology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Huaiyin, Jinan, Shandong, 250117, P.R. China.

NPJ precision oncology

|August 22, 2025

まとめ

KRASとTP53の変異は,臓がんのアウトカムに大きな影響を与える. 特定のKRASサブタイプと共変異は,患者の予後を予測し,管腺がんの個別化治療戦略を伝える.

科学分野:

腫瘍学
遺伝学
分子生物学

背景:

KRAS変異は臓管腺がん (PDAC) の進行における重要な要因です.
KRASサブタイプ内の分子異質性を理解することは,予後にとても重要です.

研究の目的:

PDACにおけるKRASサブタイプ間の分子異質性を調査する.
KRAS変異と共変異の予後的な影響を決定する.

主な方法:

病院 (SDFM),TCGA,およびQCMGコホートにおけるKRAS変異の分析.
研究された共変異 (KRAS,TP53,CDKN2A,SMAD4) と腫瘍変異負荷と結果との相関.
特定のKRASサブタイプ (G12D,Q16,その他,G12V,G12R) とTP53の予後効果を評価した.

主要な成果:

KRASとTP53,そしてTP53とCDKN2Aの共変異は,より高い腫瘍変異負荷と,より悪いアウトカムに関連していた.
KRASサブタイプG12DとQ16は,G12VとG12Rと比較して,より悪い予後を示した.
TP53状態とKRASサブタイプを組み合わせることで,より短い生存期間,PD- L1発現の増加,P53経路の変化,および免疫細胞浸透の変化 (T細胞/マクロファージの減少,中性粒子の増加) を有する高リスク患者を特定しました.

結論:

KRASとTP53の変異は,PDACにおいて有意な予後値を持っています.
KRASサブタイプとTP53状態を含む分子プロファイリングは,臓がん患者の個別化された治療アプローチを導くことができます.

さらに関連する動画

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

Utilizing High Resolution Ultrasound to Monitor Tumor Onset and Growth in Genetically Engineered Pancreatic Cancer Models

Utilizing High Resolution Ultrasound to Monitor Tumor Onset and Growth in Genetically Engineered Pancreatic Cancer Models

Published on: April 7, 2018

関連する概念動画

The Ras Gene

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...